The generic form of Novo Nordisk’s diabetic medication Victoza, which is currently unavailable in the nation, was approved by the Food and Drug Administration on Monday by Hikma Pharmaceuticals.
According to the government, reviewing generic versions of the medications that are in low supply is a top priority. Since 2023, Victoza, also known as liraglutide, has been on the FDA’s shortage list.
According to Iilun Murphy, head of the FDA’s Office of Generic Drugs, generic medications provide patients more treatment alternatives that are typically more economical.
In June, Hikma’s generic medication was initially given provisional approval. A Reuters request for comment on the drug’s price was not immediately answered by the firm.
Teva Pharmaceuticals introduced an approved generic version of Victoza in the United States earlier this year.
Adults and children with type 2 diabetes who are ten years of age or older may use the once-daily injection Victoza.
Due to the loss of patent protection last year and patients switching to more efficient once-weekly medications like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, demand for the first-generation GLP-1 has been declining.
Mounjaro and Ozempic are both members of the same class of medications known as GLP-1 agonists, which were once created to treat diabetes but are now also authorized to treat obesity.
Note: Every piece of content is rigorously reviewed by our team of experienced writers and editors to ensure its accuracy. Our writers use credible sources and adhere to strict fact-checking protocols to verify all claims and data before publication. If an error is identified, we promptly correct it and strive for transparency in all updates, feel free to reach out to us via email. We appreciate your trust and support!